NASDAQ OMX

World Conference on Lung Cancer Sunday Press Conference: Introducing New Awards and Global Guidelines

Dela

YOKOHAMA, Japan, Oct. 15, 2017 (GLOBE NEWSWIRE) -- The first press briefing at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) highlighted new awards and innovations that encourage and support the treatment of lung cancer and other thoracic malignancies; these include the recognition of outstanding care teams, introduction of new guidelines for nurses and fostering the next generation of researchers.

The press conference began with a welcome message from Conference Co-Presidents Dr. Hisao Asamura and Dr. Keunchil Park, who have worked tirelessly to make this year's conference in Yokohama a major success.

The first Cancer Care Team Award recognizes exceptional patient care
The IASLC Foundation is awarding its first-ever Cancer Care Team Award to multidisciplinary cancer care teams across the globe who go above and beyond to provide the highest-quality patient care. The award was proposed by Dr. Matthew Holman and his wife, Marilyn, a lung cancer survivor. Jill Feldman, a lung cancer survivor and advocate from the United States, introduced the award by telling her story and sharing why this award is particularly meaningful to her.

"My team at Rush University has always been patient-centered and is so deserving of this award, along with the other awardees today," said Jill Feldman. "Amazing things are possible when teams across disciplines work together to put the patient first. I am grateful to the IASLC Foundation for introducing an award that encourages this kind of extraordinary teamwork."

Teams at the following institutions were recognized with the award:

  • Guangdong Lung Cancer Institute (China)
  • Neotorax - Oncologia D'or (Brazil)
  • Instytut Gruzlicy i Chorób Pluc w Warszawie (Poland); Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii, Samodzielny Publiczny szpital Kliniczny w Warszawie (Poland); Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie w Warszawie (Poland)
  • Johns Hopkins Hospital - Sidney Kimmel Cancer Center (USA)
  • Rush University Medical Center (USA)

New guidelines for nurses provide best practices for immunotherapy treatment
At last year's WCLC in Vienna, the IASLC Nursing and Allied Health Committee identified the need for educational support for those caring for lung cancer patients receiving immunotherapy. During today's press conference, Kim Rohan of the United States and Anne Fraser of New Zealand unveiled the resulting guidelines for immunotherapy. The guidelines are an invaluable resource to nurses and cover the life-threatening adverse effects patients may experience during immunotherapy treatment including gastrointestinal, dermatologic, endocrine, ocular, hepatic, neurological and pulmonary toxicities.

"These guidelines are unique in that they are the result of international collaboration," said Anne Fraser. "As immunotherapy treatment continues to be utilized more frequently, the guidelines will be essential to helping nurses understand and mitigate the potential side effects."

IASLC Mentorship Award participants speak to the value of mentorship
The IASLC International Mentorship Program is a professional development and education program for early-career thoracic malignancy-focused physicians and researchers from economically developing countries. Thirteen mentees were selected for the 2017 program, representing specialties from medical oncology to pulmonology and hailing from Argentina, China, India, Indonesia, Malaysia, Pakistan, Saudi Arabia, Serbia and Thailand. Some of the world's leading figures in lung cancer will provide mentorship and guidance during the WCLC, as well as host the mentees at their home institutions for a week.

A number of mentors shared their experiences with the program and underscored the value of mentorship, including Fiona Blackhall of the United Kingdom, Ross Camidge of the United States, Nir Peled of Israel and Mary O'Brien of the United Kingdom.

For Prof. Blackhall, the benefits of mentorship include the ability to inspire the next generation of oncologists and cancer researchers, serve as a female role model in medicine and highlight areas of unmet need in lung cancer research. Prof. Peled found that there were mutual benefits of working with his mentee, as he has been able to enlarge his team network. Dr. Camidge, who is based in Denver, discussed his long-distance collaboration with his mentee, Harry Ren of China. They jointly diagnosed a patient who then traveled to Denver for a clinical trial, demonstrating the value of global collaboration.

Mary O'Brien also spoke to why mentorship is so critical for young professionals in the field. "Medicine is a profession traditionally taught as an apprenticeship, learning from and watching senior doctors. Medicine has changed and much is not taught through books and other sources of information. We need to remember the power of human contact. A strong mentorship scheme will bring the best out of young doctors, talents that are both obvious and hidden," said Dr. O'Brien.

Livestreams of the daily press conferences are available here.

About the WCLC
The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of "Synergy to Conquer Lung Cancer," the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit wclc2017.iaslc.org.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Contacts:             
Hillary Wasserman 
Senior Associate
HWasserman@GroupGordon.com
+1 732-778-1896

Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org
+1 720-254-9509



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: IASLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Kallelse till extra bolagsstämma den 5 september 2018. Patrick Söderlund och Hjalmar Winbladh föreslås som nya styrelseledamöter i BIMobject AB. Split 2:1 föreslås.15.8.2018 15:30Pressmeddelande

Aktieägare representerande cirka 49 procent av rösterna i BIMobject AB har meddelat att de föreslår att Hjalmar Winbladh och Patrick Söderlund väljs till nya styrelseledamöter vid en extra bolagsstämma onsdagen den 5 september 2018. Ben O'Donnell lämnar sitt uppdrag som styrelseledamot i samband med den extra bolagsstämman. Styrelsen kommer därefter att bestå av Stefan Larsson (VD), Anders Wilhjelm (ordförande), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh och Patrick Söderlund. Vidare föreslås ändrad ersättning till styrelsen. Nytt arvode utgår med 800 000 kronor, fördelat mellan styrelseordförande och Söderlund om 400 000 kronor vardera. Styrelsen föreslår även att stämman beslutar om aktieuppdelning av befintliga utestående aktier i förhållande 2:1. Patrick Söderlund, född 1973 och svensk medborgare, är Chief Design Officer samt Executive Vice President på Electronic Arts. I denna roll leder han utvecklingen av bolagets tekniska innovationer och bolagets marknadsföringsteam

BIMobject AB: Notice to attend Extraordinary General Meeting on September 5, 2018. Patrick Söderlund and Hjalmar Winbladh proposed as new Board Members in BIMobject AB. A split 2:1 is proposed.15.8.2018 15:30Pressmeddelande

Shareholders representing approximately 49 percent of the votes in BIMobject AB have announced that they propose that Hjalmar Winbladh and Patrick Söderlund are appointed new Board Members at an Extraordinary General Meeting to be held on Wednesday September 5, 2018. Ben O'Donnell resigns as Board Member in connection with the Extraordinary General Meeting. The Board will thereafter be composed of Stefan Larsson (CEO), Anders Wilhjelm (Chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund. Furthermore, a change in remuneration to the Board is proposed. The new Board fee totals SEK 800,000 and is to be divided between the Chairman and Söderlund with SEK 400,000 each. The board also proposes that the General Meeting resolves to split the company's shares 2:1. Patrick Söderlund, born in 1973 and a Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In his present role he manages the development of technology innovation

BIMobject AB: Offentliggörande av delårsrapport april - juni 201815.8.2018 08:00Pressmeddelande

Den fullständiga rapporten finns även tillgänglig på bolagets hemsida (info.bimobject.com). Andra kvartalet 2018 Faktureringen ökade med 83 procent och uppgick till 33 MSEK (18). Koncernens nettoomsättning ökade med 75 procent och uppgick till 28 MSEK (16). Fördelning mellan projekt och webservices (prenumerationer) var 40/60 procent (60/40). Bruttomarginalen ökade till 86 procent (81). Koncernens rörelseresultat förbättrades och uppgick till -15 MSEK (-17). Resultat per aktie uppgick till -0,29 SEK (-0,31) före utspädning. Kassaflödet från löpande verksamheten uppgick till -18 MSEK (-15). Ackumulerat antal användare ökade och uppgick till cirka 845 000. Ackumulerat antal nedladdningar uppgick till 25,5 miljoner. Antalet tillverkare uppgick till 1230. Styrelsen beslutade att påbörja processen för notering av bolaget vid Nasdaq Stockholm. Viktiga händelser andra kvartalet BIMobject ingår samarbete med Pipe Retail Solution för att effektivisera digital butiksplanering. BIMobject tecknar

BIMobject AB: Interim Report April - June 201815.8.2018 08:00Pressmeddelande

Second quarter 2018 Billing increased by 83 percent to SEK 33 (18) million. The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. The gross margin increased to 86 (81) percent. The Group's operating profit improved to SEK -15 (-17) million. Basic earnings per share amounted to SEK -0.29 (-0.31). Cash flow from operating activities was SEK -18 (-15) million. The accumulated number of users increased to approximately 845,000. The accumulated number of downloads amounted to 25.5 million. The number of manufacturers was 1,230. The Board decided to initiate the process of listing the Company on Nasdaq Stockholm. Significant events during the second quarter BIMobject forms strategic partnership with Pipe Retail Solution to streamline digital planning of retail spaces. BIMobject signs Letter of Intent with leading US 3D media company Matterport. CEO's comments EQT Ventures' investment

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum